Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Not Applicable

• Conditions: Hospitalized Patient
• Interventions: Other: Drug reconciliation

• Registration Number: NCT05062655
• Lead Sponsor: Centre Hospitalier le Mans

Brief Summary

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.

Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.

The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.

This new organisation is part of the policy of continuous improvement of the quality and safety of care

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-03
• Status Verified: 2021-09
• Study First Submitted: 2021-09-21
• Study First Submitted QC: 2021-09-21
• Study First Posted: 2021-09-30
• Last Update Submitted: 2022-01-07
• Last Update Posted: 2022-01-24
• Primary Completion: 2022-12-08
• Study Completion: 2022-12-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• hospitalized patient
• Patient with a drug treatment with a particular mode of supply
• Paediatric patient or an adult patient.
• First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion Criteria

• Patient under curatorship or guardianship
• Patient residing abroad
• No free, informed and written consent obtained

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Drug reconciliation	Drug reconciliation	Drug reconciliation and transmission to pharmacist

Primary Outcome Measures

Name	Time	Method
Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment	1 month after inclusion	Value of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient

Trial Locations

Locations (1)

Centre Hospitalier Du Mans; 🇫🇷 Le Mans, France